Imatinib Viatris (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This blocks downstream signaling pathways that promote malignant cell proliferation and survival, leading to reduced tumor growth and, in many cases, cancer cell death.

The dose of Imatinib Viatris is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing regimen provided by their healthcare professional.

Safety data for Imatinib in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risk mitigation with their physician.

To order Imatinib Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and Ph+ ALL. Newer agents such as dasatinib and nilotinib have broader kinase profiles and may be used when resistance or intolerance to imatinib occurs. Choice of therapy depends on disease characteristics, side‑effect profile, and patient comorbidities.

Imatinib Viatris tablets should be stored at temperatures below 25 °C (77 °F). Keep them in the original container, protect from moisture and direct sunlight, and avoid exposure to excessive heat or humidity to maintain product stability.

Imatinib Viatris is taken orally as a whole tablet with a glass of water. It may be taken with or without food, but patients should follow any specific instructions from their prescriber and avoid crushing or chewing the tablet.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiac failure, and pulmonary hypertension. Patients should be monitored regularly for blood‑count abnormalities, liver‑function changes, and cardiac symptoms, and any concerning signs should prompt immediate medical evaluation.

Imatinib is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that may cause dangerous drug‑drug interactions.